ACRV Acrivon Therapeutics, Inc. Common Stock
Healthcare$1.75-2.23%ClosedMarket Cap: $55.2M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
0.71
P/S
0.00
EV/EBITDA
-0.28
DCF Value
$0.96
FCF Yield
-120.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.4%
ROA
-71.7%
ROIC
-84.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-19.9M | $-19.0M | $— | — |
| Q4 null | $0.00 | Infinity% | $-20.1M | $-19.0M | $— | — |
| FY null | $0.00 | -Infinity% | $-84.1M | $-77.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-19.7M | $-18.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-22.6M | $-21.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-21.7M | $-19.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-25.0M | $-22.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-89.2M | $-80.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-25.1M | $-22.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-21.4M | $-18.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-17.7M | $-16.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-21.1M | $-19.3M | $-0.86 | — |